Data from MMV-supported research now in the public domain

In an unprecedented move, data from three new projects supported by MMV have been made available in the public domain.

20 May 2010

The first MMV-supported project, conducted by GlaxoSmithKline (GSK) has identified promising leads to develop new antimalarials. The second, the screening of compounds of the Genomics Institute of the Novartis Research Foundation (GNF) has been released to the European Bioinformatics Institute (EMBL-EBI). The third, conducted by Prof. Kip Guy at St Jude Children’s Research Hospital, Memphis, will also be released to the EMBL-EBI this week. Placing the combined data of over 20,000 active compounds into the public domain will give the global malaria community a considerable resource to drive forward the development of new medicines for malaria.

Download MMV's press release. [PDF: 55KB]

Data on over 20,000 compounds will be available at:

The European Bioinformatics Institute (EMBL-EBI)
Collaborative Drug Discovery
PubChem National Library of Medicine
St. Jude Children's Research Hospital


Related Information:

GSK press release: New research conducted by GlaxoSmithKline has been published in Nature identifying promising potential leads to develop new medicines to treat malaria.

In January 2010, GSK announced its intention to share data and chemical structures identified in its screening of the 2 million compounds from its library against the parasite that causes malaria using on-line resources. Together with the added intelligence in the Nature publication, scientists globally have been given thousands of chemical starting points to stimulate their research.

Download GSK's press release. [PDF: 88Kb]

Drug Discovery and Development: Paper by Frederic Bost et al ‘Informatics for neglected diseases collaborations’

Neglected diseases collaborations require a global, secure, multi-organization data-management solution, combined with a platform that facilitates communication and supports collaborative work. This review discusses the solutions offered by ‘Software as a Service’ (SaaS) web-based platforms, despite notable challenges, and the evolution of these platforms required to foster efficient virtual research efforts by geographically dispersed scientists.

Download the review from Drug Discovery & Development. [PDF: 5Mb]